HBV polymerase (reverse transcriptase)
Assets acting on this target.
- Class
- Nucleoside analogue HBV polymerase inhibitor
By indication
Related mechanisms
HBV polymerase (reverse transcriptase) drugs compared
6 drugs, stage by indication
| Drug | Developer | Modality | Furthest stage | Stage by indication |
|---|---|---|---|---|
| Entecavir (Baraclude)Baraclude | Bristol-Myers Squibb | small molecule | Approved | Approved in Chronic Hepatitis B |
| lamivudine (Epivir-HBV)Epivir-HBV | GlaxoSmithKline | small molecule | Approved | Approved in Chronic Hepatitis B |
| tenofovir alafenamide (Vemlidy)Vemlidy | Gilead Sciences | small molecule | Approved | Approved in Chronic Hepatitis B |
| Besifovir dipivoxil (Besivo) | IlDong Pharmaceutical Co., Ltd., LG Chem | small molecule | Phase 3 | Phase 3 in Chronic Hepatitis B |
| Tenofovir amibufenamide (Hengmu)Hengmu | Hansoh Pharmaceutical Group | small molecule | Phase 3 | Phase 3 in Chronic Hepatitis B |
| Entecavir (Cavir) | Hanmi Pharmaceutical | small molecule | Phase 1 | Not recorded |